仁和药业
(000650)
| 流通市值：73.36亿 | | | 总市值：77.14亿 |
| 流通股本：13.31亿 | | | 总股本：14.00亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,150,637,679.36 | 2,364,332,798.79 | 1,237,638,493.59 | 5,032,146,123.81 |
| 营业收入 | 3,150,637,679.36 | 2,364,332,798.79 | 1,237,638,493.59 | 5,032,146,123.81 |
| 二、营业总成本 | 2,593,155,629.99 | 1,915,743,640.28 | 1,057,041,354.69 | 4,045,062,750.76 |
| 营业成本 | 1,964,506,725.22 | 1,457,431,164.59 | 783,896,357.51 | 3,164,091,640.85 |
| 税金及附加 | 33,185,837.77 | 23,156,970.91 | 11,616,728.91 | 49,180,640.02 |
| 销售费用 | 359,767,057.72 | 269,193,217.28 | 174,265,236.13 | 540,433,015.43 |
| 管理费用 | 222,310,915.4 | 157,182,784.31 | 87,564,815.3 | 269,917,416.32 |
| 研发费用 | 23,201,544.61 | 17,529,061.09 | 6,468,715.89 | 46,364,854.29 |
| 财务费用 | -9,816,450.73 | -8,749,557.9 | -6,770,499.05 | -24,924,816.15 |
| 其中:利息费用 | 95,565.56 | 79,544 | 47,640.8 | 345,103.76 |
| 其中:利息收入 | 11,679,823.65 | 11,097,467.29 | 8,084,647.66 | 28,656,329.7 |
| 加:公允价值变动收益 | -720,970 | -953,370 | -849,825 | 16,828,415.64 |
| 加:投资收益 | 21,523,313.36 | 9,343,832.48 | 6,934,277.11 | 59,261,436.39 |
| 资产处置收益 | -187,405.07 | -201,621.47 | -201,621.47 | -270,195.23 |
| 资产减值损失(新) | -185,015.48 | -398,792.57 | 0 | -223,111,451.16 |
| 信用减值损失(新) | -4,562,622.58 | -4,458,218.58 | 39,789.94 | -3,923,106.26 |
| 其他收益 | 112,551,014.14 | 92,706,550.97 | 78,338,220.77 | 62,766,390.77 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 685,900,363.74 | 544,627,539.34 | 264,857,980.25 | 898,634,863.2 |
| 加:营业外收入 | 2,752,301.8 | 1,708,375.19 | 779,781.15 | 4,226,862.86 |
| 减:营业外支出 | 5,286,155.17 | 4,632,862.92 | 1,240,525.83 | 4,001,504.51 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 683,366,510.37 | 541,703,051.61 | 264,397,235.57 | 898,860,221.55 |
| 减:所得税费用 | 168,463,787.06 | 128,997,174.04 | 54,600,065.35 | 269,449,910.24 |
| 六、净利润 | 514,902,723.31 | 412,705,877.57 | 209,797,170.22 | 629,410,311.31 |
| 持续经营净利润 | 514,902,723.31 | 412,705,877.57 | 209,797,170.22 | 629,410,311.31 |
| 归属于母公司股东的净利润 | 415,677,635.65 | 337,175,704.35 | 177,296,535.93 | 567,257,498.51 |
| 少数股东损益 | 99,225,087.66 | 75,530,173.22 | 32,500,634.29 | 62,152,812.8 |
| (一)基本每股收益 | 0.3 | 0.24 | 0.13 | 0.41 |
| (二)稀释每股收益 | 0.3 | 0.24 | 0.13 | 0.41 |
| 九、综合收益总额 | 514,902,723.31 | 412,705,877.57 | 209,797,170.22 | 629,410,311.31 |
| 归属于母公司股东的综合收益总额 | 415,677,635.65 | 337,175,704.35 | 177,296,535.93 | 567,257,498.51 |
| 归属于少数股东的综合收益总额 | 99,225,087.66 | 75,530,173.22 | 32,500,634.29 | 62,152,812.8 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-30 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |